Publicacións en colaboración con investigadores/as de Imperial College London (9)

2022

  1. Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design

    American Heart Journal, Vol. 246, pp. 32-43

2021

  1. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

2020

  1. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    European Respiratory Journal, Vol. 55, Núm. 1

  2. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  4. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

2009

  1. Distribution of espM and espT among enteropathogenic and enterohaemorrhagic Escherichia coli

    Journal of Medical Microbiology, Vol. 58, Núm. 8, pp. 988-995